As the FDA continues to develop evolving guidelines, our industry has experienced a sudden, paradigm shift towards hybrid and virtual trials, with telemedicine becoming the “norm” for patient interaction across a variety of therapeutic areas. PharPoint is a strong advocate of this approach as an option to incorporate efficiencies for select indications and is positioned to advise clients as the rest of our industry adapts to this change.
On the forefront of these changes is PharPoint’s new director of clinical operations, Julie Robey. Robey brings over 20 years of drug discovery and development experience to PharPoint Research with extensive experience in infectious disease.